Filter By Industry
Filter By Tag

Newsroom

Amyndas Pharmaceuticals Press releases

1 - 1 of 1 Press Release

EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor
Aug 27, 2014
Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria.


Amyndas Pharmaceuticals RSS Feed